Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00435448 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT00435448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2005
Completion date
December 31, 2006
Enrollment
480
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, enlarged prostate